Predict the Response to Acute Treatment of Migraine With Rimegepant 75 mg

Sponsor
University of Roma La Sapienza
Study ID
NCT05888766
Status
Unknown

Conditions

  • Migraine Disorders

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Rimegepant 75 milligrams — DRUG
    At the screening visit patients with episodic migraine, which will be prescribed Rimegepant 75 mg as abortive treatment, will be asked to participate in the study.

Study Details

Tools to predict which patients could better respond to abortive CGRP target therapy are still lacking. We propose to investigate if biochemical (salivary CGRP) and neurophysiological (evoked potentials) biomarkers can recognize patients with the best chances of responding to Rimegepant 75 mg as an acute treatment of migraine.

Key Dates

Start date
Jul 1, 2023
Status verified
May 2023
Primary completion
Jul 30, 2024
Completion
Sep 30, 2024

Study Design

Enrollment
20 participants (estimated)

Arms

  • Arm: Episodic migraine patients
    20 patients with episodic migraine (\<15 attacks/month) will be recruited from a specialized headache Clinic (headache clinic of the Sapienza University of Rome, Latina).

Primary Outcome Measure

Salivary CGRP levels during attacks [ Time Frame: from enrollment to one month after the start of therapy ]

Central Contacts

Related Studies